ALERE DETERMINE HIV-1/2 AG/AB COMBO
Report
- Report Number
- 1221359-2019-00028
- Event Type
- Malfunction
- Date Received
- May 28, 2019
- Date of Event
- April 26, 2019
- Report Date
- May 28, 2019
- Manufacturer
- ALERE SCARBOROUGH, INC.
- Product Code
- MZF
- UDI-DI
- 10811877010293
- PMA / PMN Number
- BP120037-0
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- FL, US
- Reporter Occupation
- OTHER HEALTH CARE PROFESSIONAL
Narratives
TESTING WAS PERFORMED AT ALERE (B)(4) ON RETAINED KIT LOTS 103698 AND 107842 (EXP 21 JULY 2020) WITH THE FOLLOWING INTERNAL SERUM/PLASMA CONTROL SAMPLES: (B)(6) SAMPLES. ALL TEST RESULTS WERE VALID AND PERFORMED AS EXPECTED. ADDITIONALLY, THE MANUFACTURING BATCH RECORDS FOR LOTS 103698 AND 107842 WERE REVIEWED. THIS LOT MET THE REQUIRED RELEASE SPECIFICATIONS. A REVIEW OF THE COMPLAINTS REPORTED AS (B)(6) OR UNCONFIRMED (B)(6) RELATED TO LOT NUMBERS 103698 AND 107842 SHOWED THAT THE COMPLAINT RATE IS (B)(4), RESPECTIVELY. THE EVIDENCE AVAILABLE DOES NOT INDICATE THAT THE PRODUCT IS PERFORMING OUTSIDE LABEL CLAIMS. ALERE (B)(4) WAS UNABLE TO DETERMINE THE EXACT ROOT CAUSE OF THE REPORTED ISSUE. THE RESULTS OBTAINED MAY POSSIBLY BE RELATED TO THE PATIENT SAMPLE. THE SAMPLE MAY HAVE CONTAINED SPECIFIC SUBSTANCES WHICH MAY HAVE AFFECTED THE RESULTS. THE AVAILABLE EVIDENCE SUGGESTS THAT THE DEVICE LOTS ARE PERFORMING WITHIN LABELED CLAIMS.
AN INFANT RECEIVED ART TREATMENT FOR FIVE (5) DAYS POST CESAREAN BIRTH BASED ON A (B)(6) ANTIBODY (AB) RESULT OF THE MOTHER WITH THE ALERE DETERMINE HIV-1/2 AG/AB COMBO TEST. CONFIRMATORY TESTING ON THE MOTHER WITH A 4TH GENERATION HIV CHEMILUMINESCENCE TEST WAS REPORTED AS (B)(6) AND RNA VIRAL LOAD TESTING WAS REPORTED AS (B)(6).
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 440148 | ALERE DETERMINE HIV-1/2 AG/AB COMBO | IVD FOR HIV 1/2 AG/AB | MZF | ALERE SCARBOROUGH, INC. | 103698 | 10811877010293 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 1 DA |